Joren Madsen, MD, DPHL
Basic profileCardiothoracic Surgeon · Massachusetts General Hospital
Joren Madsen is Cardiothoracic Surgeon at Massachusetts General Hospital. OpenAlex indexes 404 publications with 10,333 citations (h-index 53); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles in the findmyKOL directory.
Overview
Updated 12 Oct 2026
Joren Madsen, MD DPHL, is Cardiothoracic Surgeon at Massachusetts General Hospital. The public record shows 409 publications with 10,623 citations (h-index 53), centered on Transplantation: Methods and Outcomes, Organ and Tissue Transplantation Research, T-cell and B-cell Immunology. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 4 companies, 18 NIH-funded awards (1996–2026).
- Most recent indexed publication: 2026 · Xenotransplantation
- Top research focus: Transplantation: Methods and Outcomes
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 12 Oct 2026. Every fact links its source below.
Research focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 165.
Clinical & industry
trials, payments and federal fundingContact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
55 Fruit Street, Boston, MA 02114
Clinical trials
Updated 12 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Belatacept in Heart Transplantation
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Tocilizumab in Lung Transplantation
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Tocilizumab in Cardiac Transplantation
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Industry payments
Updated 12 Oct 2026
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TransMedics, Inc.Program year20241 payment
- CSL BehringProgram year20232 payments$28,000openpaymentsdata.cms.gov ↗
- TransMedics, Inc.Program year20233 payments$10,439openpaymentsdata.cms.gov ↗
NIH funding
Updated 12 Oct 2026
18 NIH research awards on record, funded 1996–2026 per NIH RePORTER. The latest:
- Novel Approaches to Inducing Lung Allograft Tolerance in NHPs
Massachusetts General Hospital
FY2026$3,401,842U19AI174967 - Targeting trained immunity in transplantation
Icahn School of Medicine at Mount Sinai
FY2026$2,685,855P01AI168258 - Using trained immunity-inhibiting nanobiologics to achieve tolerance of heart allografts in non-human primates
Icahn School of Medicine at Mount Sinai
FY2026$919,879P01AI168258
Publications
Updated 12 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance.
Circulation
Article2026 - The inhibitory receptor Siglec-E controls antigen-presenting cell activation and T cell-mediated transplant rejection.
Science translational medicine
Article2025 - Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation.
Science translational medicine
Article2025 - Early Renal Outcomes Following Heart Transplantation Using Organs Procured After Circulatory Death.
Journal of the American Heart Association
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Trained immunity — basic concepts and contributions to immunopathologyReview451 citations2022
- 03Transplantation Outcomes with Donor Hearts after Circulatory DeathArticle356 citations2023
- 04A Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and AlloantibodyArticle252 citations2011
- 05Cardiac Operations in Patients 80 Years Old and OlderArticle240 citations1997
Network
Updated 12 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 12 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ctsnet.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ctsnet.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”